https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-03 / Front Immunol 2015;6:91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-03 / Front Immunol 2015;6:912015-03-03 00:00:002019-02-15 08:45:08Dendritic cell-based vaccine efficacy: aiming for hot spots
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-02 / Exp. Biol. Med. (Maywood) 2015 Oct;240(10):1310-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-02 / Exp. Biol. Med. (Maywood) 2015 Oct;240(10):1310-82015-03-02 00:00:002019-02-15 08:52:36Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-02 / Biomed Res Int 2015;2015:127828
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-02 / Biomed Res Int 2015;2015:1278282015-03-02 00:00:002015-03-02 00:00:00Inhibitory and apoptosis-inducing effects of Newcastle disease virus strain AF2240 on mammary carcinoma cell line
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-01 / Mol. Biol. (Mosk.) 2015 Mar-Apr;49(2):195-204
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-01 / Mol. Biol. (Mosk.) 2015 Mar-Apr;49(2):195-2042015-03-01 00:00:002019-02-15 09:22:42[Expressing foreign genes by Newcastle disease virus for cancer therapy]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-01 / Anticancer Res. 2015 Mar;35(3):1575-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-01 / Anticancer Res. 2015 Mar;35(3):1575-822015-03-01 00:00:002019-02-15 08:48:13Matched-pair analysis of dendritic cell versus targeted-therapy in patients with metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-01 / Tumori 2015 Mar-Apr;101(2):e54-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-01 / Tumori 2015 Mar-Apr;101(2):e54-62015-03-01 00:00:002019-02-15 09:37:55Concomitant trimodality therapy of re-irradiation, chemotherapy and regional hyperthermia for a pretreated inoperable sarcoma recurrence
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-02-26 / Gynecol. Oncol. 2015 May;137(2):335-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-02-26 / Gynecol. Oncol. 2015 May;137(2):335-422015-02-26 00:00:002019-02-15 08:52:21Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-02-26 / J. Nucl. Med. 2015 Apr;56(4):530-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-02-26 / J. Nucl. Med. 2015 Apr;56(4):530-72015-02-26 00:00:002019-02-15 09:37:54PET response criteria in solid tumors predicts progression-free survival and time to local or distant progression after chemotherapy with regional hyperthermia for soft-tissue sarcoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-02-20 / Cancer Res. 2015 Apr;75(8):1760-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-02-20 / Cancer Res. 2015 Apr;75(8):1760-92015-02-20 00:00:002019-02-15 09:00:11Hyperthermia Sensitizes Glioma Stem-like Cells to Radiation by Inhibiting AKT Signaling
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-02-16 / Int. Immunopharmacol. 2015 Apr;25(2):450-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-02-16 / Int. Immunopharmacol. 2015 Apr;25(2):450-62015-02-16 00:00:002019-02-15 08:45:38Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer
